87 related articles for article (PubMed ID: 20973931)
1. Oncogenic RAF: a brief history of time.
Solit D; Rosen N
Pigment Cell Melanoma Res; 2010 Dec; 23(6):760-2. PubMed ID: 20973931
[No Abstract] [Full Text] [Related]
2. BRAF signaling and targeted therapies in melanoma.
Dhomen N; Marais R
Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery: How melanomas bypass new therapy.
Solit D; Sawyers CL
Nature; 2010 Dec; 468(7326):902-3. PubMed ID: 21164474
[No Abstract] [Full Text] [Related]
4. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Bahadoran P; Allegra M; Le Duff F; Long-Mira E; Hofman P; Giacchero D; Passeron T; Lacour JP; Ballotti R
J Clin Oncol; 2013 Jul; 31(19):e324-6. PubMed ID: 23715574
[No Abstract] [Full Text] [Related]
5. Resistance to BRAF inhibition in melanomas.
Solit DB; Rosen N
N Engl J Med; 2011 Feb; 364(8):772-4. PubMed ID: 21345109
[No Abstract] [Full Text] [Related]
6. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
[TBL] [Abstract][Full Text] [Related]
7. The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
Davis MJ; Schlessinger J
J Cell Biol; 2012 Oct; 199(1):15-9. PubMed ID: 23027900
[TBL] [Abstract][Full Text] [Related]
8. Effectively targeting BRAF in melanoma: a formidable challenge.
Fecher LA; Amaravadi R; Schuchter LM
Pigment Cell Melanoma Res; 2008 Aug; 21(4):410-1. PubMed ID: 18710372
[No Abstract] [Full Text] [Related]
9. B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
Karki P; Li X; Schrama D; Fliegel L
J Biol Chem; 2011 Apr; 286(15):13096-105. PubMed ID: 21345796
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
[TBL] [Abstract][Full Text] [Related]
12. The natural history of malignancies under conditions of BRAF inhibitor stimulation.
White RM
Expert Opin Investig Drugs; 2011 Jan; 20(1):135-6. PubMed ID: 21117980
[No Abstract] [Full Text] [Related]
13. FDA approves vemurafenib for treatment of metastatic melanoma.
Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
[No Abstract] [Full Text] [Related]
14. BRAF as therapeutic target in melanoma.
Wellbrock C; Hurlstone A
Biochem Pharmacol; 2010 Sep; 80(5):561-7. PubMed ID: 20350535
[TBL] [Abstract][Full Text] [Related]
15. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Oberholzer PA; Kee D; Dziunycz P; Sucker A; Kamsukom N; Jones R; Roden C; Chalk CJ; Ardlie K; Palescandolo E; Piris A; MacConaill LE; Robert C; Hofbauer GF; McArthur GA; Schadendorf D; Garraway LA
J Clin Oncol; 2012 Jan; 30(3):316-21. PubMed ID: 22067401
[TBL] [Abstract][Full Text] [Related]
16. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
17. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept, ipilimumab, and vemurafenib.
Hussar DA; Au AY
J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
[No Abstract] [Full Text] [Related]
20. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
Murphy DA; Makonnen S; Lassoued W; Feldman MD; Carter C; Lee WM
Am J Pathol; 2006 Nov; 169(5):1875-85. PubMed ID: 17071608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]